Skip to main content

Francina Munell Casadesus

Institutions of which they are part

Main researcher
Pediatric Neurology
Vall Hebron Institut de Recerca

Francina Munell Casadesus

Institutions of which they are part

Main researcher
Pediatric Neurology
Vall Hebron Institut de Recerca

Projects

Acciones de la SHBG y de los receptores de estrógenos en el desarrollo y la progresión a la hormono-resistencia del cáncer de próstata.

IP: Francina Munell Casadesus
Collaborators: Joan Morote Robles
Funding agency: Instituto de Salud Carlos III
Funding: 108215
Reference: PI020772
Duration: 06/11/2002 - 06/11/2005

Investigación y desarrollo de productos y tecnologías de diagnóstico-pronóstico y aplicaciones terapéuticas en la enfermedad neoplásica.

IP: Jaume Reventós Puigjaner
Collaborators: Francina Munell Casadesus, Josep Castellví Vives, Antonio Gil Moreno
Funding agency: Oncnosis Pharma, AIE
Funding: 249550
Reference: CENIT/01/2006
Duration: 19/01/2006 - 31/12/2009

RTICC - Red Temática de Investigación cooperativa de cáncer

IP: Jaume Reventós Puigjaner
Collaborators: Joan Morote Robles, Ma Teresa Quiles Pérez, Francina Munell Casadesus, Eva Colas Ortega, Enric Trilla Herrera, Silvia Cabrera Diaz, Antonio Gil Moreno, Marta Rebull Santamaria, Tomàs Pinós Figueras, RTICC - Red Temática de Investigación cooperativa de cáncer, Marina Rigau Resina, Carles Xavier Raventós Busquets, Maria Antonia Arbos Via, Jacques Planas Morin, Josep Roma Castanyer
Funding agency: Instituto de Salud Carlos III
Funding: 350549.54
Reference: RD06/0020/0058
Duration: 02/01/2007 - 31/12/2013

Mecanismos moleculares responsables del desarrollo de resistencia a los andrógenos en el cáncer de próstata. Identificación de marcadores predictivos de progresión y de respuesta al tratamiento

IP: Francina Munell Casadesus
Collaborators: Joan Morote Robles
Funding agency: Instituto de Salud Carlos III
Funding: 90440
Reference: PI052684
Duration: 01/01/2006 - 31/05/2009

Related news

The ClinPrior algorithm achieved a positive diagnosis rate of 70% in two minority diseases of neurodegenerative origin, which represents double the number of cases that are diagnosed with current tools.

Over the course of two days, experts presented the latest advances in vectors, different gene modification techniques and their transfer to clinical practice.

El 20% dels pacients en els quals s’havia trobat alguna predisposició genètica van ser diagnosticats amb algun tipus de tumor i van poder iniciar el tractament de manera precoç.

Related professionals

Montserrat Moreno Sánchez

Montserrat Moreno Sánchez

Postdoctoral researcher
Read more
Borja Garcia Centrich

Borja Garcia Centrich

Tècnic/a Grau Superior
Unitat legal
Legal Directorate
Read more
David Berlana Martín

David Berlana Martín

Research technician
Basic, Translational and Clinical Pharmacy Research
Read more
Mireia Caralt Barba

Mireia Caralt Barba

Hepato-bilio-pancreatic surgery (HBP) and liver transplantation
Read more

Subscribe to our newsletters and be part of the Campus life

We are a world-leading healthcare complex where healthcare, research, teaching and innovation go hand in hand.

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.